Halper Sadeh investigates Repare Therapeutics' $1.82/share deal with XenoTherapeutics over fairness and fiduciary duties.

Halper Sadeh LLC has launched an investigation into Repare Therapeutics' proposed $1.82 per share cash deal with XenoTherapeutics, including non-transferable contingent value rights tied to future partnership payouts. The probe focuses on whether Repare’s board fulfilled fiduciary duties, if the offer is fair, and if restrictions on competing bids or insider benefits undermine shareholder value. The firm is seeking better terms for investors on a contingency basis with no upfront cost.